Dr. Akira Miyauchi, MD – President, Kuma Hospital | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

Akira Miyauchi, MD, PhD

Kuma Hospital
8 Chome-2-35 Shimoyamatedori
Chuo Ward
Kobe, Japan

Akira Miyauchi is President and Chief Operating Officer (COO) of Kuma Hospital, Center for Excellence in Thyroid Care, Kobe, Japan. He is an endocrine surgeon, especially interested in thyroid and parathyroid diseases. He earned his MD and PhD at Osaka University Medical School in 1970 and 1978, respectively. He was Associate Professor in Department of Surgery, Kagawa Medical University until he was appointed to Vice President of Kuma Hospital in 1998. Since 2001, he is at his present position.

Dr. Miyauchi is currently serving as Chairman of the Asian Association of Endocrine Surgeons. He also served as Council of the International Association of Endocrine Surgeons (IAES) until August 2015. He is a Visiting Professor of Surgery at Nippon Medical School, Tokyo, Japan and Belgrade University, Belgrade, Serbia. He was appointed as President-Elect of the IAES in August 2017 and will serve as President of the IAES from 2019 for 2 years.

Dr. Miyauchi has published more than 519 papers in English and more than 496 papers in Japanese International Invited Lectures and Special Lectures: 36 times, including ones at Massachusetts General Hospital, Yale University, Mayo Clinic, Johns Hopkins Hospital, University of California San Francisco, Seoul National University, and University of Rome Sapienza. 


Representative Publications:

Exploratory Analysis of Prognostic Factors for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer

A Case With Poorly Differentiated Follicular Carcinoma of the Thyroid Produced and Secreted CEA

Prognostic Factors of Anaplastic Thyroid Carcinoma

Ultrasonographically and Anatomopathologically Detectable Node Metastases in the Lateral Compartment as Indicators of Worse Relapse-Free Survival in Patients With Papillary Thyroid Carcinoma

Expression of Cdc25b and Cdc25a in Medullary Thyroid Carcinoma: Cdc25b Expression Level Predicts a Poor Prognosis

A Therapeutic Strategy for Incidentally Detected Papillary Microcarcinoma of the Thyroid